Idecabtagene vicleucel

Multiple myeloma

Unassigned

New Medicines

Relapsed or refractory multiple myeloma

Information

Advanced therapy medicinal product (ATMP)
Celgene
Celgene

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Anti-BCMA chimeric antigen receptor (CAR)-T cell therapy.
MM is the second most common haematological cancer, responsible for 15-20% of deaths from haematological cancer and about 2% of all deaths from cancer. Incidence in Europe is 4.5-6.0 per 100,000 per year with a mortality rate of 4.1 per 100,000 per year [3].
Relapsed or refractory multiple myeloma
Intravenous infusion

Evidence based evaluations